Natural Language Processing

Hearing Loss

Phenotype Description:  individuals with sensorineural hearing loss (SNHL)
Below are algorithms used to identify individuals with SNHL at BioVU. If you have questions regarding any of the information presented on this page, you may contact either:
Wei-Qi Wei at wei-qi.wei@vanderbilt.edu or Joshua Denny at josh.denny@vanderbilt.edu

Final

Hypothyroidism

Project Outline:  Selection of all Caucasian patients with hypothyroidism without a secondary cause of surgical removal or radiological ablation.  The search is designed to eliminate subclinical hypothyroidism (by requiring that patients be on a replacement medication), medication-induced hypothyroidism (e.g., PTU, lithium, or history of amiodarone), and transient causes (e.g., pregnancy or subacute thyroiditis).

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Identification of Fibromyalgia Patients in a Rheumatoid Arthritis Cohort

Fibromyalgia has been estimated to affect 12-17% of rheumatoid arthritis patients (1, 2). 

This algorithm was created to identify fibromyalgia patients in a population of rheumatoid arthritis patients. The gold standard used for diagnosis of fibromyalgia was that the treating rheumatologist made a clinical diagnosis of fibromyalgia. Rheumatoid arthritis patients were identified by using a previously validated algorithm (3). 

Algorithm included the following conditions: 

Owner Phenotyping Groups: 
Final

Liver cancer staging project

Hepatocellular carcinoma (HCC), the primary form of liver cancer, is one of the leading cancer-related causes of death worldwide. There are many complex treatment strategies; the populations are heterogeneous, with different genetic, lifestyle, and comorbity differences.

Here we describe the algorithm used to identify HCC liver cancer stages for AJCC, BCLC, and CLIP liver cancer staging systems.

Algorithm:

Step 1) Patient files and laboratories

Final

Peripheral Arterial Disease - 2012

Peripheral Arterial Disease (PAD) is prevalent with approximately 10-12 million adults in US affected. For those with PAD, morbidity and mortality are high and quality of life is markedly impaired. The genetic basis of PAD is poorly understood and is the focus of the Mayo Clinic Electronic Medical Records and Genomics (eMERGE) Network study.

Owner Phenotyping Groups: 
View Phenotyping Groups: 
Final

Pages